Answers are grounded in this paper and cite their sources.
OBJECTIVE: To conduct a clinical trial of intratympanic steroid injection for idiopathic sudden sensorineural hearing loss in subjects who failed oral steroid therapy. STUDY DESIGN AND SETTING: Open-label methylprednisolone injection clinical trial in a tertiary neurotologic referral center. Twenty subjects (14 males; 6 females) received 4 injections within a 2-week period (4 days apart). Hearing, dizziness, and tinnitus were evaluated before and after treatment. RESULTS: There were no serious unexpected adverse events and 2 types of expected adverse events (tympanic membrane perforation, nausea after injection). No increases in dizziness or tinnitus lasting longer than 24 hours were observed after injections. One of 20 (5%) improved to near-normal hearing. In addition, there was statistically significant improvement in 4-frequency pure-tone average and speech discrimination score at 1 month after treatment. CONCLUSION: Four intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids. SIGNIFICANCE: A clinical trial of intratympanic injections for idiopathic sudden hearing loss was successfully completed and promising results were found.
No takes yet. Share an insight, caveat, or question.
Slattery et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: